Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

4.8%

1 terminated/withdrawn out of 21 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

10%

2 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

9 recruiting

Enrollment Performance

Analytics

Phase 2
8(53.3%)
N/A
4(26.7%)
Early Phase 1
1(6.7%)
Phase 3
1(6.7%)
Phase 4
1(6.7%)
15Total
Phase 2(8)
N/A(4)
Early Phase 1(1)
Phase 3(1)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (21)

Showing 20 of 21 trials
NCT05728268Phase 2Recruiting

Neoadjuvant Dose-dense Chemotherapy for HR+/HER2- Breast Cancer Patients With High Proliferation Index

Role: collaborator

NCT03649503Recruiting

The National Registry Study For the Real-world Patients With Parkinsonian Disorders in China

Role: collaborator

NCT05305859Phase 2Recruiting

Venetoclax Combining Chidamide and Azacitidine (VCA) in the Treatment of R/R AML

Role: collaborator

NCT06926985Early Phase 1Withdrawn

An Exploratory Clinical Study of Anti-CD19/BCMA Chimeric Antigen Receptor NK Cell Injection in the Treatment of IgA Nephropathy

Role: lead

NCT06039748Completed

Angiography-Derived Quantitative Functional Assessment Versus Pressure-Derived FFR and IMR: The FAIR Study

Role: collaborator

NCT06904183Phase 2Recruiting

Lenvatinib, Sintilimab, and DEB-TACE With/Without HAIC for HCC >7 cm With PVTT

Role: collaborator

NCT06926959Recruiting

Tricuspid RegurgitAtion rIsk modeL Study (TRAIL Study)

Role: collaborator

NCT06827899Phase 2Recruiting

Veneclax, Chidaniline Combined With Azacitidine Followed by Decitabine + MAG Regimen in the Treatment of Elderly Untreated AML

Role: collaborator

NCT05603884Phase 2Recruiting

VCA Regimen Followed by D-MAG Regimen on the Treatment of Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)

Role: collaborator

NCT06158386Phase 2Recruiting

Chidamide Combined With Linperlisibon for the Treatment of Refractory/Relapsed Follicular Lymphoma

Role: collaborator

NCT05520619Phase 2Active Not Recruiting

Combination of Tislelizumab and Chemoradiotherapy in Esophageal Cancer (EC-CRT-002)

Role: collaborator

NCT06265883Completed

Lenvatinib Plus DEB-TACE With/Without FOLFOX-HAIC for Large HCC With PVTT

Role: collaborator

NCT06227286Not ApplicableNot Yet Recruiting

Enhanced External Counter Pulsation on Afterload Mismatch Rate in Post-TEER (PAMPER)

Role: collaborator

NCT06220630Unknown

The Characteristics, Treatment Patterns and Prognosis of Chinese Male Breast Cancer: A Real-world Study

Role: collaborator

NCT06069232Recruiting

Aortic Valve Diseases RISk facTOr assessmenT and Prognosis modeL Construction

Role: collaborator

NCT05848102Phase 4Unknown

Dapagliflozin Effect on FunctiOnal Mitral Regurgitation and Myocardial Fibrosis (DEFORM)

Role: collaborator

NCT04718909Phase 2Unknown

Regorafenib Plus Sintilimab vs. Regorafenib as the Second-line Treatment for HCC

Role: collaborator

NCT05420480Not ApplicableNot Yet Recruiting

Two-field Versus Three-field Lymph Node Dissection in ESCC After Neoadjuvant Therapy

Role: collaborator

NCT04808661Not ApplicableUnknown

EndovaScular Versus mediCaL mAnagement of Uncomplicated Type B Intramural heMatoma Trial (ESCLAIM)

Role: collaborator

NCT03016858Phase 3Unknown

Clinical Trial of Thoracoscopic Bullectomy Surgery Under Spontaneous Ventilating Anesthesia

Role: collaborator